Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Severe Renal Impairment Who Have Inadequate Glycemic Control

NCT03242018 is registered in ClinicalTrials.gov with Lexicon Pharmaceuticals as lead sponsor.

NCT NCT03242018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03242018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Severe Renal Impairment Who Have Inadequate Glycemic Control
Lead sponsor
Lexicon Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
August 16, 2017
Completion date
December 11, 2019
Enrollment
277 (actual)
Sites
106

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease stage 4, type 2 diabetes mellitus